Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $1.42, $0.69 better than the analyst estimate of $0.73. Revenue for the quarter came in at $302.4 million versus the consensus estimate of $260.52 million.

"I want to thank healthcare providers and our employees for the perseverance they showed during the second quarter to ensure patients had uninterrupted access to INGREZZA under the challenging circumstances caused by the COVID-19 pandemic. As we move into the second half of 2020, we remain focused on improving the diagnosis and treatment rates for people with tardive dyskinesia, preparing to make ONGENTYS available to people living with Parkinson's disease, and advancing our programs in clinical development," said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. "With four U.S. FDA approved treatments that address four unique patient populations and a diverse and expanding pipeline, Neurocrine Biosciences is well positioned to be a leading neuroscience-focused biopharmaceutical company."

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.